Semax

What it is

Semax is a lab-made peptide, a chain of 7 amino acids: methionine, glutamic acid, histidine, phenylalanine, proline, glycine and proline (Met-Glu-His-Phe-Pro-Gly-Pro)¹². The first four match positions 4 to 7 of ACTH (adrenocorticotropic hormone), the pituitary hormone that tells the adrenal glands to make cortisol¹. Its developers started from a natural ACTH fragment, ACTH(4-10), whose effect lasts only 30 to 60 minutes, and replaced its last three amino acids with a proline-glycine-proline tail; they report that semax’s effect lasts 20 to 24 hours¹. They also report that it has neither corticotropic (cortisol-releasing) nor melanocyte-stimulating activity, and the Russian label says it has no hormonal activity¹³. How it works is not settled. In rats, nasal doses of 50 or 250 µg/kg raised BDNF (brain-derived neurotrophic factor), a protein that supports nerve cells, in the basal forebrain within 3 hours, but not in the cerebellum¹⁵. In the lab it blocks enzymes in human serum that break down enkephalins, the body’s own opioid-like peptides¹⁶. In rodents it raised a serotonin breakdown product in the striatum, a deep brain region, and strongly boosted the dopamine release caused by amphetamine; FDA calls this ‘concerning because increased dopaminergic tone in the striatum is a response typically induced by drugs of abuse such as cocaine’²¹⁷. It is broken down quickly: in the presence of nerve cells it is cut mainly into two shorter pieces, HFPGP and the Pro-Gly-Pro tail²¹⁸.

Work on semax began in the late 1970s under N. F. Myasoedov and I. P. Ashmarin, and it was made at the Institute of Molecular Genetics of the Russian Academy of Sciences¹¹⁹. A 0.1% nasal drop came first, and a stronger 1% drop for stroke had been developed by 2001¹. Both are now registered in Russia to the company Peptogen, under registrations that Vidal dates to 2025 and that replaced older ones³⁴. Much of the human evidence comes from the developers’ circle: Ashmarin co-wrote the 1996 study in healthy men, Myasoedov co-wrote a 1997 stroke study, and a 2013 English-language review of semax and selank was co-written by Myasoedov¹⁷⁸. In the US, Wells Pharmacy Network and LDT Health Solutions asked FDA to let pharmacies compound it, then withdrew; FDA reviewed it anyway for its July 2026 advisory meeting².

Benefits: what the research shows

Nearly all human data come from Russian studies of the nasal drops, often small, published in Russian and without a placebo group²⁵. FDA’s 2026 review set aside the Russian-language stroke papers because full English translations were not available, and it found ‘insufficient evidence’ for cerebral ischemia (poor blood flow to the brain), migraine or trigeminal neuralgia (a facial nerve pain)². The largest stroke study we could read in full, from 2018, split 110 patients in rehabilitation after ischemic stroke into groups with or without semax, described as random, with no placebo or blinding reported⁶. The semax groups got 6,000 µg a day for 10 days, twice, 20 days apart. At 1 month, scores on the Barthel index, a 0 to 100 scale of everyday self-care, rose more with semax: 21.6 versus 11.3 points when rehabilitation started early (about 3 months after the stroke) and 14.8 versus 4.1 when it started late (about 7 months). At 5 months, total gains no longer differed in the early group (27.5 versus 25.8 points) but still did in the late group (23.7 versus 18.7). Blood levels of BDNF also rose with semax⁶. A 1997 study compared 30 acute stroke patients given semax with 80 similar patients on usual care and reported ‘some influence’ on the recovery of movement and other functions⁷. A 2005 study of 187 people with long-term poor brain blood flow reported less disease progression and fewer strokes, but its English summary gives no figures²³. In an open trial in 27 people with motor neuron disease (ALS), semax did not change nerve tests or disease scores, though quality-of-life scores rose²⁴. Other uses rest on even smaller studies. In 32 adults with hard-to-heal peptic ulcers, ulcers had healed by day 14 in 89.5% of those given semax drops on top of standard ulcer drugs versus 30.8% of controls²²⁵. Russian eye studies reported benefits in optic nerve disease and in diabetic eye damage, including when semax was driven into the nose lining with a weak electric current²⁶²⁷. For pain, FDA reviewed a 1996 study of one nasal dose with no control group or blinding: 4 of 12 people with migraine said their headache stopped 90 to 120 minutes after the dose, 8 reported weaker relief, and the 16 with typical trigeminal neuralgia had no change². For focus and memory, the data in healthy people are thin. A 1996 study of 19 healthy men reported EEG (brain-wave) changes like those of nootropic (memory-enhancing) drugs and better work performance for 20 to 24 hours after 0.25 to 1.0 mg, but its summary mentions no placebo group²⁸. A 1997 review by the developers reported better memory and attention in healthy men working under extreme conditions, and no side effects in any patient²⁸. Two placebo-controlled studies, in 24 and 52 healthy volunteers, measured only brain-scan patterns at rest, not thinking or memory²⁹³⁰. No semax trial is registered on ClinicalTrials.gov (searched 7 October 2026)³¹. Animal data are broader: in rats with induced strokes, nasal semax given twice in the first hour and then daily for 6 more days made the damaged area about 20% smaller at 8 days and protected memory in a learning test²³².

Key human studies

Doses studied

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

Half-life

No human value found; lab and animal figures range from minutes to over an hour¹²FDA found no study of how semax is absorbed, spread or cleared in people by any route². In rats it is rapidly broken down, and its main breakdown product is Pro-Gly-Pro². Very little reaches the brain: FDA cites peak brain levels of about 0.005% of an IV dose and 0.072% of a nasal dose (at 2 minutes) in rats, while the developers’ review gives 0.01% and 0.093%¹². The developers’ review gives conflicting figures, a half-life ‘in the body of a few minutes’ and more than 1 hour in serum, and says effects last 20 to 24 hours after a single dose, which it links to active breakdown pieces¹.

Routes

• Nasal drops (Russia’s 0.1% and 1% products; every human study FDA found used the nose)
• Nasal spray (sold by US clinics and online sellers; no human data found on these products)
• Subcutaneous injection, under the skin (proposed for US compounding and sold online; no human data found)
• Endonasal electrophoresis, a weak current that carries the drug into the nose lining (Russian eye studies and the 0.1% label)
• Intraperitoneal (into the abdomen) or intravenous injection (animal studies only)

Every dose studied for Semax, with sources →

Legal status

United States

Not approved by FDA for any use: FDA’s 2026 review says semax has no United States Pharmacopeia or National Formulary monograph and is not a component of any FDA-approved drug². FDA notes that semax ‘is a common name and not a United States Adopted Name (USAN)’, and that it has seen multiple salts and derivatives, including different active molecules, sold under the same name². No semax trial is registered on ClinicalTrials.gov: a search on 7 October 2026 returned no studies³¹. A Kentucky compounding pharmacy pleaded guilty to distributing unapproved new drugs from 25 October 2018 to 1 April 2020; its plea agreement says these included semax and selank. On 24 February 2021 it was sentenced to 3 years of probation and forfeited $1,788,906.82, its 2019 sales of these products³⁵. In a 10 November 2021 warning letter to an Indianapolis firm, FDA noted that semax, selank and several other peptides ‘were not nominated for inclusion on the 503A bulks list’ at that time³⁶.

US pharmacies

Section 503A of federal drug law covers compounding by pharmacies for individual patients. FDA added ‘Semax (heptapeptide)’ to Category 2 of its interim 503A bulks list, substances that raise significant safety concerns, in its 29 September 2023 update³⁷. Its nominators, Wells Pharmacy Network and LDT Health Solutions, had proposed a nasal spray or an injection under the skin at 7,500 or 1,000 µg/mL, and FDA reviewed it for cerebral ischemia, migraine and trigeminal neuralgia; both nominations were withdrawn². A law firm reported that on 15 April 2026 FDA announced it would remove semax and 11 other peptides from Category 2 because their nominators had withdrawn them; the firm stressed that removal does not make them eligible for compounding³⁸. Semax is in no category of the list updated 14 May 2026, so US pharmacies cannot lawfully compound it under section 503A⁹. FDA’s safety-risk page lists it under ‘Bulk drug substances nominated but withdrawn’, substances ‘previously in category 2’ whose nominators withdrew them. It says semax ‘may pose risk for immunogenicity’ (unwanted immune reactions) and that the agency ‘lacks sufficient information to know whether the drug would cause harm if administered to humans’¹⁰. FDA reviewed the free base and the acetate salt on its own initiative and, in a review dated 11 May 2026, concluded that the balance of criteria ‘weighs against’ adding either². On 24 July 2026 PCAC (FDA’s Pharmacy Compounding Advisory Committee) voted 8 for and 5 against adding semax, with 1 abstention⁵. Members in favor framed it as recognizing a decision ‘patients are already making’; dissenters pointed to weak preclinical evidence, characterization concerns and the risk of steering patients away from evidence-based therapies for serious conditions⁵. The vote is not binding: as a law firm notes, FDA must still go through formal rulemaking before a substance is permanently added to the list³⁸. As of 5 October 2026 the meeting page, last updated 6 August 2026, listed no minutes, and the 503A list had not changed⁹¹¹. No 503B outsourcing facility (a larger compounder registered with FDA) has reported compounding semax since 2019².

Other countries

Russia: Vidal, a Russian drug reference, lists two prescription-only semax nasal drops registered to Peptogen. Semax 1% (registration ЛП-№(010596)-(РГ-RU), dated 18 June 2025, replacing Р N000812/01) is for the acute period of moderate or severe ischemic stroke, as part of combined treatment³. Semax 0.1% (ЛП-№(009449)-(РГ-RU), dated 26 March 2025, replacing ЛС-002553) lists memory and thinking problems from blood-vessel disease of the brain, recovery after stroke, brain injury, neurosurgery or anesthesia, prevention of mental fatigue, optic nerve disease and, from age 7, minimal brain dysfunction including ADHD⁴. Vidal shows both on Russia’s list of vital and essential medicines³⁴. FDA’s review, citing the Russian register, also says semax is registered in Russia as 0.1% and 1% nasal drops, and that no monograph exists in the European, Japanese or International pharmacopeias². The official Russian register (GRLS) could not be opened for this article. Canada: Health Canada lists semax and selank among unauthorized injectable peptides seized from and sold by an online seller (1 August 2025), says injectable peptides are regulated as prescription drugs in Canada, and says ‘For Research Use Only’ labels do not make products legal³⁹⁴⁰. Belgium: Sciensano, Belgium’s public health institute, identified semax and selank in two suspicious preparations encountered at the end of 2017 and 2018⁴¹. Australia: semax is not named in the Poisons Standard in force from 1 October 2026. Corticotrophin (ACTH) is in Schedule 4 (prescription only), and the standard’s entries also cover derivatives, judged on structural, pharmacological and toxicological similarity, so whether that entry could reach semax is unresolved; we found no ruling³⁴. UK and EU: not verified.

Sport

Semax is not named on WADA’s (World Anti-Doping Agency) 2026 Prohibited List or on the 2027 List, which takes effect on 1 January 2027¹²³³. Class S0 bans substances not covered elsewhere ‘with no current approval by any governmental regulatory health authority for human therapeutic use’; the 2027 List adds ‘peptides’ to its examples¹²³³. By our reading, Russia’s current approval of semax nose drops puts it outside S0³⁴. The harder question is S2 (peptide hormones, growth factors, related substances and mimetics). S2 bans ‘corticotrophins and their releasing factors’, such as corticorelin and tetracosactide, and says that ‘other substances with similar chemical structure or similar biological effect(s)’ are also prohibited¹²³³. Semax contains 4 amino acids of ACTH, a corticotrophin, and its Russian label describes it as a synthetic analog of corticotropin, but the same label and its developers say it has no hormonal activity¹³. We found no WADA ruling either way, so we mark its status unclear. WADA’s note on the 2027 List says that even if a peptide is not named, ‘utmost caution should be taken as it may still be prohibited and may be harmful to health’¹³.

Semax in the legal tracker →

Quality and the gray market

What testing finds

Finnrick, an independent testing service, lists 5 semax tests from 3 sellers between 12 March 2026 and 9 September 2026: 2 passed, 1 failed and 2 were incomplete under its ‘purity focus’ standard (purity of at least 99.5% and dose within 35% of the label)¹⁴⁴³. One seller’s samples passed on 12 March 2026, failed on 27 May 2026 and passed again on 9 September 2026¹⁴. Incomplete tests do not count toward the pass rate, and 5 tests are too few to judge the market⁴³. FDA’s review found that the lab certificates (certificates of analysis) sent with both nominations were titled for semax acetate but listed the formula, weight and CAS number of the free base². They allowed single impurities of up to 1.0% or 2.0% without saying what they were, and gave no results for clumping (aggregation) or microbes; FDA found no bacterial toxin (endotoxin) testing in published sources either². FDA also had ‘strong concerns’ about nasal sprays because nothing was known about their container, closure and pump². On one US seller’s site (accessed 5 October 2026), the ‘Semax’ page listed a formula and weight matching an acetylated, amidated variant (C39H54N10O10S, 854.99), while its ‘N-Acetyl Semax’ page listed plain semax’s formula with a weight (858.97) that fits neither form²¹⁴⁴. In Belgium, Sciensano identified semax and selank in two suspicious preparations encountered at the end of 2017 and 2018⁴¹. No FDA sampling or recall of semax was found.

How it is sold

In pages it viewed in December 2025, FDA found US health and wellness clinics, concierge medical services, functional and regenerative medicine clinics and online retailers marketing semax injections and nasal products for anxiety, depression, attention and memory, stroke, nerve regeneration, diabetic neuropathy, ADHD, opioid withdrawal, ALS, Parkinson’s and Alzheimer’s disease, optic nerve atrophy, pain and stomach protection². Many sites did not clearly say whether the products were compounded, and none said whether they contained the free base or a salt². One site sold a 2.5 mg/mL injection and a 1.25 mg/mL nasal spray, alone or as a ‘50:50’ blend with selank; another offered 30 mg ‘for research purposes only’². Online sellers also offer research-labeled vials: one US seller listed semax 25 mg at $63 and ‘N-Acetyl Semax’ 25 mg at $60, ‘sold for laboratory research use only’ (accessed 5 October 2026)²¹⁴⁴. A nootropics site whose author discloses a paid relationship with sellers calls semax ‘safe to use if you follow dosage recommendations’⁴². Demand signals are thin: Finnrick had logged only 5 semax tests by 9 September 2026¹⁴. Health Canada has seized semax sold online³⁹, and a Kentucky pharmacy whose plea agreement names semax among the unapproved drugs it distributed forfeited $1,788,906.82 in 2021³⁵.

Side effects and risks

• Unknown safety for the ways it is used in the US: FDA found no human data on how semax is absorbed or cleared, no human data at all for injection under the skin, and too little clinical information to characterize the safety of nasal use².
• Unwanted immune reactions: FDA says semax ‘may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities’²¹⁰.
• Bleeding: in rats, nasal semax raised anti-clotting and clot-dissolving activity in the blood; FDA says this raises concern about bleeding, especially in people at risk of bleeding or taking other drugs that raise that risk².
• Possible abuse potential: in rodents semax strongly boosted amphetamine’s dopamine release, a response FDA links to drugs of abuse, and FDA found no study of whether semax itself is habit-forming²¹⁷.
• Seizures and mental health: the Russian labels rule out use in acute psychiatric disorders, anxiety disorders or with a history of seizures³⁴. A 1999 study in 73 patients with brain damage from lack of oxygen reported, in some cases, episodes of abnormal (paroxysmal) EEG activity after semax and advised giving the first dose under EEG monitoring⁴⁵.
• Missing safety studies: FDA found no studies of genetic damage (genotoxicity) or of effects on fertility and development; one study in a tumor-prone mouse strain reported smaller breast tumors, which FDA said should be interpreted with caution².
• Age and pregnancy limits: the 1% label rules out use under 18, the 0.1% label under 7, and both rule out pregnancy and breastfeeding, noting that no clinical studies were done in them³⁴.
• Wrong or mislabeled product: FDA warns that inconsistent naming means patients ‘may be dosed with a different’ substance than the doctor ordered, one seller’s pages listed formulas that did not match their product names, and 1 of 5 Finnrick tests failed²¹⁴⁴⁴. At the July 2026 meeting, the acting chair warned that the name could be confused with semaxanib, a different compound⁵.
• Few reports do not mean few harms: compounders under section 503A generally do not report adverse events to FDA, and FDA found only one adverse event report for semax².
• Legal and sport risk: a Kentucky pharmacy whose plea agreement names semax among the unapproved drugs it distributed was sentenced in 2021, Health Canada has seized semax products, and its status under the sport banned list is unclear¹³³⁵³⁹.

Documented harms

• May 2024A consumer reported directly to FAERS (the FDA Adverse Event Reporting System, report #25343150) eye pain and eye burning in May 2024 after using Semax 0.1% nasal drops bought online. The report says the person was hospitalized and that the eye pain had not resolved when it was filed in May 2025. It was the only semax report FDA’s search of FAERS found through 3 December 2025, and FDA found no case reports in the medical literature².
• 1999In a Russian study of 73 patients with brain damage after oxygen loss, 14 of them in a persistent vegetative state, EEG recordings in some cases showed episodes of paroxysmal (abnormal burst) activity after semax was given; the authors advised that the first dose be given while monitoring brain activity⁴⁵.

Questions people ask

What is still unknown

• Is semax’s registration current in the official Russian State Register of Medicines (GRLS)? Vidal lists both registrations and FDA cites the register, but GRLS showed a CAPTCHA and could not be checked directly.
• Was the 1996 study of healthy men placebo-controlled or randomized? Only its abstract could be read, and it mentions neither.
• What did the pediatric studies FDA lists (120 children aged 12 to 14 with depression; 331 children with tics) find? FDA saw only meeting abstracts, and we could not open them.
• What doses did two human studies really use? FDA lists 600 mg a day for 10 days in a 2002 meeting abstract on chronic ischemic brain disease, 30 times the 1% label’s daily maximum of 20 mg, and 0.5 mg/kg once in a 1996 pain study; neither original could be opened. The 600 mg may be a slip for 600 µg, a mix-up found in the English summary of a 2013 semax study.
• Is semax approved anywhere besides Russia? Other countries’ registers were not checked.
• Does WADA’s S2 ban on corticotrophins and similar substances cover semax? No WADA ruling was found.
• Does Australia’s corticotrophin entry, which also covers derivatives, extend to semax? No ruling was found.
• Will FDA act on its advisers’ 24 July 2026 vote? As of 5 October 2026 no minutes or FDA decision had been posted.
• What are the safety and effects of N-acetyl semax and amidated variants sold online? No human data were found.
• What did the vials Finnrick tested contain? Only pass, fail and incomplete results are public; purity and content figures need a login.
• What is the legal status of semax in the UK and EU? Not verified.
• How large is US demand? Reddit and Google Trends could not be checked for this article.

Sources

1. 1A New Generation of Drugs: Synthetic Peptides Based on Natural Regulatory Peptides Neuroscience & Medicine (Scientific Research Publishing), Dec 2013. scirp.org
2. 2FDA Evaluation of Semax-Related Bulk Drug Substances (Semax (Free Base) and Semax Acetate), PCAC briefing document U.S. Food and Drug Administration, 11 May 2026. fda.gov
3. 3Семакс (Semax) 1% nasal drops: instructions for use Vidal Russia drug reference, 18 Mar 2021. vidal.ru
4. 4Семакс (Semax) 0.1% nasal drops: instructions for use Vidal Russia drug reference, 17 Mar 2021. vidal.ru
5. 5The PEPTIDE-L Wave Rolls On! PCAC Adds Two More Bulk Drug Substances for the 503A List FDA Law Blog (Hyman, Phelps & McNamara), 28 Jul 2026. thefdalawblog.com
6. 6The efficacy of semax in the tretament of patients at different stages of ischemic stroke (in Russian) Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2018. pubmed.ncbi.nlm.nih.gov
7. 7Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study) (in Russian) Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 1997. pubmed.ncbi.nlm.nih.gov
8. 8Synthetic ACTH analogue Semax displays nootropic-like activity in humans Neuroscience Research Communications, Sep 1996. doi.org
9. 9Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
10. 10Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov
11. 11July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, 6 Aug 2026. fda.gov
12. 12World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
13. 13Summary of Major Modifications and Explanatory Notes: 2027 Prohibited List World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
14. 14Semax Safety Testing Results & Vendor Ratings Finnrick, 9 Sep 2026. finnrick.com
15. 15Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain Journal of Neurochemistry, Apr 2006. pubmed.ncbi.nlm.nih.gov
16. 16Semax and selank inhibit the enkephalin-degrading enzymes from human serum (in Russian) Bioorganicheskaia Khimiia, May 2001. pubmed.ncbi.nlm.nih.gov
17. 17Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents Neurochemical Research, Dec 2005. pubmed.ncbi.nlm.nih.gov
18. 18Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation (in Russian) Bioorganicheskaia Khimiia, Mar 2006. pubmed.ncbi.nlm.nih.gov
19. 19Development of Peptide Biopharmaceuticals in Russia Pharmaceutics, 27 Mar 2022. pubmed.ncbi.nlm.nih.gov
20. 20ACTH (4-7), Pro-Gly-Pro- (semax; PubChem CID 9811102) PubChem, National Center for Biotechnology Information, accessed 7 Oct 2026. pubchem.ncbi.nlm.nih.gov
21. 21N-Acetyl Semax Peptide for Sale (25mg) Core Peptides (vendor), accessed 5 Oct 2026. corepeptides.com (seller page, deliberately not linked)
22. 22Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties Journal of Inorganic Biochemistry, Nov 2016. pubmed.ncbi.nlm.nih.gov
23. 23Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency (in Russian) Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2005. pubmed.ncbi.nlm.nih.gov
24. 24The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax (in Russian) Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2007. pubmed.ncbi.nlm.nih.gov
25. 25Therapy of peptic ulcer with semax peptide Bulletin of Experimental Biology and Medicine, Jul 2002. pubmed.ncbi.nlm.nih.gov
26. 26Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease (in Russian) Vestnik Oftalmologii, Jan 2000. pubmed.ncbi.nlm.nih.gov
27. 27The results of the application of the pre-formed physical factors and neuroprotective therapy for the rehabilitative treatment of the patients with diabetic retinopathy (in Russian) Voprosy Kurortologii, Fizioterapii, i Lechebnoi Fizicheskoi Kultury, Sep 2013. pubmed.ncbi.nlm.nih.gov
28. 28A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study) (in Russian) Zhurnal Vysshei Nervnoi Deiatelnosti imeni I.P. Pavlova, Mar 1997. pubmed.ncbi.nlm.nih.gov
29. 29Effects of Semax on the Default Mode Network of the Brain Bulletin of Experimental Biology and Medicine, Sep 2018. pubmed.ncbi.nlm.nih.gov
30. 30Functional Connectomic Approach to Studying Selank and Semax Effects Doklady Biological Sciences, Jan 2020. pubmed.ncbi.nlm.nih.gov
31. 31ClinicalTrials.gov search for ‘semax’ (0 studies) ClinicalTrials.gov, accessed 7 Oct 2026. clinicaltrials.gov
32. 32Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex Bulletin of Experimental Biology and Medicine, Dec 2006. pubmed.ncbi.nlm.nih.gov
33. 33World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
34. 34Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
35. 35Nicholasville Compounding Pharmacy and Its Owner Sentenced for Unlawful Distribution of Prescription Drugs U.S. Attorney’s Office, Eastern District of Kentucky, 24 Feb 2021. justice.gov
36. 36Warning letter to Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine (MARCS-CMS 615908) U.S. Food and Drug Administration, 10 Nov 2021. fda.gov
37. 37Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list updated 29 September 2023) U.S. Food and Drug Administration (copy hosted by the Alliance for Pharmacy Compounding), 29 Sep 2023. join.a4pc.org
38. 38FDA to Remove 12 Popular Peptides from the Category 2 ‘Do Not Compound’ List Frier Levitt, 16 Apr 2026. frierlevitt.com
39. 39Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks (RA-77807) Health Canada, 1 Aug 2025. recalls-rappels.canada.ca
40. 40Think twice before injecting peptides bought online: unauthorized products can seriously harm you (RA-81874) Health Canada, 9 Apr 2026. recalls-rappels.canada.ca
41. 41The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind Drug Testing and Analysis, Mar 2020. pubmed.ncbi.nlm.nih.gov
42. 42Semax Nootropics Expert, 5 Sep 2026. nootropicsexpert.com
43. 43Methodology Finnrick, accessed 5 Oct 2026. finnrick.com
44. 44Semax Peptide for Sale (25mg) Core Peptides (vendor), accessed 5 Oct 2026. corepeptides.com (seller page, deliberately not linked)
45. 45Use of semax at a follow-up of patients with posthypoxic encephalopathy (in Russian) Anesteziologiia i Reanimatologiia, Jan 1999. pubmed.ncbi.nlm.nih.gov